This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.30, signifying a -0.87% move from its prior day's close.
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
by Zacks Equity Research
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
by Ekta Bagri
Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
by Zacks Equity Research
Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
Company News for Dec 27, 2023
by Zacks Equity Research
Companies In The Article Are: INTC,RYZB,BMY,NIO,MANU
Yes Virginia, There Is a Santa Claus Rally
by Mark Vickery
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Company News for Dec 26, 2023
by Zacks Equity Research
Companies In The Articles: KRTX, BMY, NKE, TCEHY, RKLB
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
by Zacks Equity Research
Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.26, marking a +0.59% move from the previous day.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar
by Zacks Equity Research
Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.
Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).
5 Stocks to Watch on Their Recent Dividend Hike
by Nalak Das
Five stocks that have recently raised dividends are: BMY, PWR, CARR, AVGO, OC.
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
by Zacks Equity Research
Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
by Zacks Equity Research
Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.